Structure Therapeutics Inc.

GPCR

Explore Our Financial Data > Companies > Structure Therapeutics Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
GPCR
CIK0001888886
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address611 GATEWAY BLVD SUITE 223, SOUTH SAN FRANCISCO, CA, 94080
Website structuretx.com
Phone(628) 229-9277
CEORaymond Stevens
EmployeesN/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$0.00
Pre-Tax Income$-140.69 million
Net Income$-141.20 million
Net Income to Common$-141.20 million
EPS$-0.80
View All
Balance Sheet
Cash$799.62 million
Assets$1.58 billion
Liabilities$67.54 million
Common Equity$1.52 billion
Liabilities & Equity$1.58 billion
View All
Cash Flow Statement
Net Income$-141.20 million
Cash From Operating Activities$-222.20 million
Cash From Investing Activities$89.80 million
Cash From Financing Activities$762.52 million
Change in Cash$630.11 million
View All
Calculations
NOPAT$-123.59 million
EBITDA$-175.23 million
Price to EarningsN/A
Price to Book$6.23
ROE-11.86%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Assessing Structure Therapeutics (GPCR) Valuation After Recent Share Price Weakness

Valuation and recent performance snapshot Structure Therapeutics (GPCR) has drawn attention after recent trading moves, leaving the stock around US$53.11 per share, with a market value near US$3.9b, and a wide gap between shorter term and longer term returns. See our latest analysis for Structure Therapeutics. Short term share price momentum has been soft, with a 1 day share price return of 2.87% decline and a 30 day share price return of 6% decline. The 1 year total shareholder return is...

Article Link

Guggenheim Remains Bullish on Eli Lilly (LLY) Ahead of Q1 2026 Results

Eli Lilly and Company (NYSE:LLY) is included in our list of the 14 hedge fund favorites with strong setup in 2026. On March 30, 2026, Guggenheim updated its model ahead of the first-quarter data and lowered the firm’s price target for Eli Lilly and Company (NYSE:LLY) from $1,168 to $1,163, while keeping a “Buy” rating. […]

Article Link

How to Play Lilly Stock Post Oral Obesity Pill Foundayo's Approval

LLY wins FDA nod for oral obesity pill Foundayo, boosting shares as it eyes billions in sales and a fast catch-up to rivals in the booming GLP-1 market.

Article Link

LLY Stock Up on GLP-1 Pill Approval: Can it Outpace NVO's Wegovy Pill?

Eli Lilly stock gains on FDA nod for oral obesity drug Foundayo, expanding its portfolio and patient access, setting up a fresh showdown with Novo Nordisk in the GLP-1 market.

Article Link

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset. The following five companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify ... These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Article Link